GLPwatch
Obesity
Approved indication
Last updated 2026-09-22 06:05 UTCFDA-approved GLP-1 drugs for obesity include Saxenda (liraglutide), Wegovy (semaglutide), and Zepbound (tirzepatide), with semaglutide specifically studied in multiple trials (e.g., STEP program) for its effects on weight loss, appetite, and energy intake in adults with obesity or overweight.
AI summary of the sources below.
How Obesity connects
- Drugs SaxendaWegovyZepbound
- Molecules LiraglutideSemaglutideTirzepatide
- Research 3,118 papers
Approved GLP-1 drugs (3)
Research (50)
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
- The Discovery and Development of Liraglutide and Semaglutide.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Semaglutide lowers body weight in rodents via distributed neural pathways.
- Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
- Obesity Management in Adults: A Review.
- Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- Once-Weekly Semaglutide in Adolescents with Obesity.
Common questions
- Which GLP-1 drugs are FDA-approved for Obesity?
- Saxenda, Wegovy and Zepbound are FDA-approved for obesity.
- Is there research on GLP-1 drugs for Obesity?
- GLPwatch tracks 3118 research papers on GLP-1 drugs and obesity. This research is investigational and does not imply FDA approval.